论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
输血后继发性黄荨麻疹
Authors Chen W, Wang H, Zhong S, Lu L, Peng C
Received 10 November 2024
Accepted for publication 2 June 2025
Published 12 June 2025 Volume 2025:18 Pages 1471—1473
DOI https://doi.org/10.2147/CCID.S501776
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Anne-Claire Fougerousse
Wan Chen,1,* Henghong Wang,1,* Shangjie Zhong,1,* Lan Lu,2,* Changen Peng1,*
1Department of Dermatology, Chengdu Pidu District Hospital of Traditional Chinese Medicine, Pidu, Chengdu, People’s Republic of China; 2Department of Pharmacy, Anti-Infective Agent Creation Engineering Research Centre of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Changen Peng, Department of Dermatology, Chengdu Pidu District Hospital of Traditional Chinese Medicine, No. 169 Zhong Xin Road, Pidu, Chengdu, Sichuan, 611730, People’s Republic of China, Email Mikepen@qq.com
Introduction: Yellow urticaria (YU) is a rare variant of urticaria characterized by a transient yellow rash. It usually occurs at patients with hyperbilirubinemia. In clinic, the vasodilation and extravasation associated with urticaria facilitate the precipitation of bilirubin within the elastin fibers of the cutaneous tissue, which consequently leads to the emergence of atypical yellow papules and plaques. The occurrence of hyperbilirubinemia in cases of yellow urticaria is commonly attributed to underlying liver diseases, including infectious hepatitis, metastatic disease of the liver, liver cirrhosis due to various causes. Here, we report a case of YU secondary to platelet transfusion.
Purpose: Red and purple rashes are common, whereas yellow wheals are rarely reported. Therefore, we are supposed to keep an eye on the diagnosis of YU.
Patients and Methods: We present a case of YU secondary to platelet transfusion that responds rapidly to anti-hypersensitive and antihistamine treatment.
Results: Based on the skin lesion and histopathology result, we considered that the patient developed YU. The patient with YU responds rapidly to anti-hypersensitive and antihistamine treatments, with no adverse effects or recurrence. The prognosis of YU is with favorable outcome. It seldom turns into chronic urticaria and occurs repeatedly.
Conclusion: The exact pathogenesis of yellow urticaria remains uncertain. It has been proposed that the yellow coloration of the disease may result from the increased capillary permeability that cytokines and mediators, especially histamine, induce. Yellow hives are attributed to underlying hyperbilirubinemia with skin deposits and suggest underlying causes, particularly liver diseases. Conventional anti-hypersensitive and antihistamine treatments are effective in treating YU. Prophylactic and systematical use of antihistamine agents may prevent relapse.
Keywords: yellow urticaria, antihistamines, hyperbilirubinemia, platelet transfusion